Date: 2013-06-25
Type of information: Collaboration agreement
Compound: auristatin-based ADC technology
Company: Bayer (Germany) Seattle Genetics (USA - WA)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration
Action mechanism: ADCs are monoclonal antibodies that are designed to selectively deliver cytotoxic agents to tumor cells.
Disease:
Details: * On June 25, 2013, Seattle Genetics has announced that it has entered into a new antibody-drug conjugate (ADC) collaboration with Bayer HealthCare (Bayer). Under the latest relationship, Bayer will be able to utilize Seattle Genetics’ auristatin-based ADC technology with antibodies to several oncology targets. The German group is responsible for research, product development, manufacturing and commercialization of all products under the collaboration. Today, there are more than 15 ADCs in clinical development using Seattle Genetics' technology. One of them, Adcetris®(brentuximab vedotin), has already received approval for two indications (relapsed or refractory CD30+ Hodgkin lymphoma (HL).
Financial terms: Bayer will pay upfront and option exercise fees of up to $20 million for worldwide rights to utilize Seattle Genetics’ auristatin-based ADC technology with antibodies to several oncology targets. Seattle Genetics is also eligible to receive up to approximately $500 million in potential milestone payments, as well as royalties on worldwide net sales of any resulting products under the multi-target collaboration.
Latest news:
